The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 21st 2025
The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
Cancer Care in the Age of COVID-19: Dr Patricia Salber Interviews Dr Bobby Reddy
August 5th 2020Patricia Salber, MD, MBA, of The Doctor Weighs In, and Sandeep “Bobby” Reddy, MD, an oncologist at Harbor-UCLA Medical Center and chief medical officer of NantHealth, discuss the clinical care of patients with cancer in the age of COVID-19.
Listen
Experts Highlight COVID-19 Vaccine Developments and Remaining Challenges
August 4th 2020The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.
Read More
The Race to Find a COVID-19 Vaccine
July 28th 2020The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.
Read More
Tocilizumab Caused Serious AEs in a Quarter of Children With Rheumatic Inflammatory Diseases
July 25th 2020In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.
Read More
One in 5 Patients With MS Don't Adhere to Oral DMDs
July 24th 2020The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.
Read More
Secukinumab Dose Escalation, Retention Rate, and Safety in Real-World Settings
July 23rd 2020In 2 studies of secukinumab use in real-world settings, researchers identified the usefulness of dose escalation in patients with psoriatic arthritis (PsA), as well as the safety, retention rate, and factors associated with drug survival among patients with PsA and ankylosing spondyloarthritis.
Read More
Therapy Provides Readily Available Stem Cell Source to Treat Rare Genetic Diseases
July 22nd 2020Umbilical cord blood provides a readily available source of stem cells to provide better access to hematopoietic stem cell transplantation to safely and effectively treat various noncancerous genetic disorders in children.
Read More
Evaluating the Presence and Impact of Comorbidities in Rheumatoid Arthritis
July 22nd 2020Comorbidities are common in patients with rheumatoid arthritis, and the presence of comorbidities reduces the chance of remission and is associated with worse functional status and disease activity measures.
Read More
Experimental Vaccines Show Promise Against COVID-19 in Healthy Subjects
July 21st 2020Two experimental vaccines, one from AstraZeneca and the other from CanSino Biologics, have shown promising results against coronavirus disease 2019 (COVID-19) in a phase 1/2 trial and a phase 2 trial. Results for both were published in The Lancet.
Read More
FDA Approves At-Home Therapy to Treat Myelodysplastic Syndromes
July 11th 2020A new oral therapy approved by the FDA will provide patients with myelodysplastic syndromes, who typically visit a health care facility for intravenous treatment, with an oral at-home option that can be beneficial during the coronavirus pandemic.
Read More
Factors Affecting Efficacy of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis
July 9th 2020Treatment options for psoriatic arthritis and axial spondyloarthritis are increasing, and with studies already identifying response predictors for tumor necrosis factor inhibitors, there is a need to predict response to the interleukin-17A inhibitor secukinumab.
Read More
Patients With SLE Experienced Delayed Access to Hydroxychloroquine During COVID-19 Pandemic
July 8th 2020Patients with systemic lupus erythematosus (SLE) may consider hydroxychloroquine essential to their treatment, but after the drug was identified as a potential therapy for coronavirus disease 2019 (COVID-19), patients with SLE experienced reduced access to the treatment, which could increase the risk of SLE flare.
Read More
FDA Lifts Partial Hold for Phase 2 Trial of R/R Hodgkin Lymphoma Therapy
July 8th 2020FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.
Read More
Physician Leaders’ Perspectives About Balancing Clinical and Leadership Responsibilities
July 6th 2020Although most physician leaders from 22 organizations saw patients and felt that it improved their leadership performance, their perceptions of the optimal balance of clinical and leadership responsibilities varied.
Read More
Pence Touts COVID-19 Progress While Task Force Highlights Growing Number of Cases
June 26th 2020In its first briefing in 2 months, the White House Coronavirus Task Force addressed rising cases of coronavirus 2019 (COVID-19) and positive test rates across states in the South, as well as the new data that show the majority of new cases are occurring in younger Americans.
Read More
Selinexor Approved Under Accelerated Pathway to Treat DLBCL
June 24th 2020The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The oral treatment is to be used after at least 2 lines of systemic therapy.
Read More
AI Smartphone App Could Improve Diagnosis of Psoriasis, Atopic Dermatitis, Eczema
June 23rd 2020Inflammatory skin diseases are often diagnosed by "first impression" and can be easily misdiagnosed. A new smartphone app using artificial intelligence (AI) may be able to assist with the diagnosis of psoriasis, atopic dermatitis, and eczema.
Read More
Dr C. Patrick Carroll Discusses Treating Patients With SCD-Related Pain Who Arrive in the ED
March 12th 2020When patients present to the emergency department (ED) with sickle cell disease (SCD)–related pain, they often have been experiencing that pain for days, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Watch